Tularemia is a disease of animals and humans caused by the bacterium Francisella tularensis. Rabbits, hares, and rodents are especially susceptible and often die in large numbers during outbreaks. Humans can become infected through several routes, including tick and deer fly bites, skin contact with infected animals, ingestion of contaminated water, or inhalation of contaminated dusts or aerosols. In addition, humans could be exposed as a result of bioterrorism. Symptoms vary depending upon the route of infection. Although tularemia can be life-threatening, most infections can be treated successfully with antibiotics. Steps to prevent tularemia include use of insect repellent, wearing gloves when handling sick or dead animals, and not mowing over dead animals. In the United States, naturally occurring infections have been reported from all States except Hawaii.
The Entomological Society of America (ESA) recently released a statement supporting the creation and implementation of a national strategy using Integrated Tick Management to better control tick populations and reduce the rapidly escalating impact of tick-borne diseases such as Rocky Mountain spotted fever, tularemia, and Lyme disease.
Tick-borne diseases are a major public health problem around the world. Ticks carry and transmit a variety of microbes that cause disease. These illnesses, which include Lyme disease, Rocky Mountain spotted fever, and Tularemia, can cause a variety of symptoms, often serious and sometimes deadly.
Research led by scientists at St. Jude Children's Research Hospital has identified key molecules that trigger the immune system to launch an attack on the bacterium that causes tularemia.
When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer.
Bernard Arulanandam, UTSA Jane and Roland Blumberg Professor in Biology and Assistant Vice President for Research Support, has been named a fellow of the American Association for the Advancement of Science. Arulanandam was elected by his peers for the honor, recognizing his scientific and socially distinguished efforts to advance science and its applications.
Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia.
CRISPR, a system of genes that bacteria use to fend off viruses, is involved in promoting antibiotic resistance in Francisella novicida, a close relative of the bacterium that causes tularemia.
Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).
Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.
Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).
Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2014.
Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.
Tularemia, aka "rabbit fever," is endemic in the northeastern United States, and is considered to be a significant risk to biosecurity -- much like anthrax or smallpox -- because it has already been weaponized in various regions of the world.
In the case of a bioterror attack, Saint Louis University will operate a medication dispensing station for students, faculty, staff and their families, offering quick access to medicines and easing the burden on local health departments so they can serve residents who lack similar access to lifesaving drugs.
Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis.
Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro's vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants.
CRISPR, a system of genes that bacteria use to defend themselves against viruses, has been found to be involved in helping some bacteria evade the mammalian immune system.
Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.
Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2012.